Addenbrooke's Cognitive Examination
Also known as: ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination
The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The ACE-R/ACE-III is appropriate for comprehensive cognitive assessment in patients with suspected dementia, particularly when differential diagnosis between Alzheimer's disease and frontotemporal dementia is clinically important. It is more thorough than the MMSE yet more efficient than formal neuropsychological testing. The ACE is indicated in secondary care (neurology, geriatric medicine, memory clinics) rather than primary care screening. It is NOT diagnostic alone and should be integrated with imaging, clinical assessment, and sometimes additional neuropsychological testing.
Strengths & limitations
- Comprehensive yet brief — assesses five major cognitive domains in 15–20 minutes, balancing breadth with efficiency.
- Excellent differentiation between dementia types — profile-based interpretation distinguishes Alzheimer's from frontotemporal dementia better than global scores.
- Superior to MMSE for detecting mild cognitive impairment and dementia — more sensitive than the MMSE across the cognitive spectrum.
- Internationally validated — extensively used and normed across multiple languages and countries.
- Longer than MMSE — 15–20 minutes limits utility in very busy primary care settings or cognitively impaired patients with limited stamina.
- Language and education dependent — several subtests require strong verbal and language abilities; results may be confounded in non-native speakers or those with aphasia.
- Requires training for administration and scoring — more complex than the MMSE; standardization demands clinician familiarity with procedures.
- Not diagnostic for Alzheimer's disease — while ACE profile can suggest pathology, definitive diagnosis requires imaging, biomarkers, and clinical judgment.
Frequently asked
What is the difference between ACE, ACE-R, and ACE-III?
The original ACE (2000) was the first version. ACE-R (2006) added items and improved norms; it is more sensitive than the original. ACE-III (2013) is the latest with further refinement. ACE-R and ACE-III are recommended for current clinical use. Score comparisons across versions are not directly valid; track changes within the same version.
How do I interpret an ACE-R score of 80 in a highly educated professional?
An ACE-R score of 80 is below the normal threshold (88+) but not severely impaired. In a highly educated individual, this may represent mild cognitive decline. However, education-adjusted norms should be consulted. Consider serial testing to track change; a declining trend is more meaningful than a single score.
Can the ACE-R be used to diagnose Alzheimer's disease?
No. The ACE-R can suggest Alzheimer-like cognitive patterns (memory > fluency impairment) but does not diagnose Alzheimer's disease. Diagnosis requires clinical assessment, imaging (MRI or PET), biomarkers (CSF or blood tau/amyloid), and sometimes neuropathology. The ACE-R is a cognitive screening tool, not a diagnostic test.
What should I do if a patient scores very low on ACE-R language items due to aphasia?
Aphasia confounds ACE-R language subscale scoring. Document the language impairment separately and interpret language-dependent items with caution. Focus on non-language domains (attention, visuospatial function) for cognitive assessment. Consider alternative tests less dependent on language if comprehensive assessment is needed.
Sources
- Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620. DOI: 10.1212/WNL.55.11.1613 ↗
- Mioshi, E., Dawson, K., Mitchell, J., Arnold, R., & Hodges, J. R. (2006). The Addenbrooke's Cognitive Examination Revised (ACE-R): A brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry, 21(11), 1078-1085. DOI: 10.1002/gps.1610 ↗
- Hsieh, S., Schubert, S., Hoon, C., Mioshi, E., & Hodges, J. R. (2013). Validation of the Addenbrooke's Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 36(3-4), 242-250. DOI: 10.1159/000351671 ↗
How to cite this page
ScholarGate. (2026, June 3). Addenbrooke's Cognitive Examination. ScholarGate. https://scholargate.app/en/neuropsychology/addenbrookes-cognitive-examination
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Alzheimer's Disease Assessment Scale-CognitiveNeuropsychology↔ compare
- Frontal Assessment BatteryNeuropsychology↔ compare
- Mattis Dementia Rating ScaleNeuropsychology↔ compare
- Mini-Mental State ExaminationNeuropsychology↔ compare
- Saint Louis University Mental Status ExaminationNeuropsychology↔ compare